Background-Atrial natriuretic peptide (ANP) is a hormone with numerous beneficial cardiovascular effects. Recently, a mutation in the ANP gene, which results in the generation of a mutant form of ANP (mANP), was identified and shown to cause atrial fibrillation in people. The mechanism(s) through which mANP causes atrial fibrillation is unknown. Our objective was to compare the effects of wild-type ANP and mANP on atrial electrophysiology in mice and humans. Methods and Results-Action potentials (APs), L-type Ca 2+ currents (I Ca,L ), and Na + current were recorded in atrial myocytes from wild-type or natriuretic peptide receptor C knockout (NPR-C −/− ) mice. In mice, ANP and mANP (10-100 nmol/L) had opposing effects on atrial myocyte AP morphology and I Ca,L . ANP increased AP upstroke velocity (V max ), AP duration, and I Ca,L similarly in wild-type and NPR-C −/− myocytes. In contrast, mANP decreased V max , AP duration, and I Ca,L , and these effects were completely absent in NPR-C −/− myocytes. ANP and mANP also had opposing effects on I Ca,L in human atrial myocytes. In contrast, neither ANP nor mANP had any effect on Na + current in mouse atrial myocytes. Optical mapping studies in mice demonstrate that ANP sped electric conduction in the atria, whereas mANP did the opposite and slowed atrial conduction. Atrial pacing in the presence of mANP induced arrhythmias in 62.5% of hearts, whereas treatment with ANP completely prevented the occurrence of arrhythmias. Conclusions-These findings provide mechanistic insight into how mANP causes atrial fibrillation and demonstrate that wildtype ANP is antiarrhythmic.
A trial fibrillation (AF) is a highly prevalent cardiac arrhythmia 1, 2 and is a major clinical problem because of the fact that current therapeutic approaches have significant limitations. 3 AF, which is characterized by the rapid and irregular activation of the atria, can occur in association with many cardiovascular disorders (ie, heart failure and hypertension) or in the absence of structural disease (lone AF). 4, 5 Lone AF is known to occur in association with genetic mutations in, for example, ion channels and gap junction proteins. [6] [7] [8] [9] Recently, a mutation in the NPPA gene, which encodes the cardioprotective hormone atrial natriuretic peptide (ANP), 10 was identified and linked to the occurrence of AF. 11 This mutation is characterized by a 2-base pair deletion in exon 3, which causes a frameshift that abolishes the stop codon and extends the normal reading frame. This NPPA mutation results in the production of a 40-amino acid mutant ANP (mANP) consisting of the normal 28-amino acid ANP with an abnormal 12-amino acid carboxyl terminal extension.
ANP is one member of a family of NPs that also includes B-type NP (BNP) and C-type NP (CNP). 10, 12 ANP is produced in atrial myocytes and is released into the circulation in response to atrial stretch. ANP is best known for its ability to regulate blood volume and blood pressure through effects in the kidneys (natriuresis and diuresis) and blood vessels (smooth muscle relaxation and endothelial permeability). 10 We have recently demonstrated that NPs have potent effects on cardiac electrophysiology. [13] [14] [15] [16] For example, BNP and CNP can increase action potential (AP) duration (APD) in association with increases in L-type Ca 2+ current (I Ca,L ) in atrial myocytes. 13 We have also shown that wild-type NPs (BNP and CNP) can potently increase electrical conduction in the sinoatrial node and atrial myocardium. 17 Wild-type ANP is able to elicit its physiological effects by binding to 2 NP receptors (NPRs) called NPR-A and NPR-C. 10, 18, 19 NPR-A is a particulate guanylyl cyclase receptor. When bound to ANP, NPR-A increases guanylyl cyclase activity and the production of cyclic GMP, which can modulate several downstream signaling proteins, including protein kinase G and phosphodiesterases. 10, 20 NPR-C is coupled to the activation of inhibitory G-proteins that reduce adenylyl cyclase activity and intracellular cAMP (cAMP) levels. 21, 22 NPR-C activates inhibitory G-proteins through a specific inhibitory G-protein activator domain located in the 37-amino acid intracellular portion of the receptor. 23, 24 mANP was found to circulate at concentrations 5 to 10× greater than wild-type ANP in patients affected by this mutation, and it has been hypothesized that this leads to enhanced effects of ANP that could create an electrophysiological substrate for AF. 11, 25 However, the ionic and molecular mechanism(s) through which mANP causes AF in humans are currently unknown. Accordingly, the goal of this study was to compare the effects of wild-type ANP and mANP on atrial electrophysiology in mouse and human atrial tissues. Our findings demonstrate that ANP and mANP have opposing effects on atrial electrophysiology because of the activation of distinct signaling pathways. These findings may explain how mANP leads to AF and also provide new insight into the electrophysiological effects of wild-type ANP in the atria.
Methods
An expanded Methods section is available in the Data Supplement.
Mice
This study used wild-type and NPR-C knockout (NPR-C −/− ) 14, 26 mice between the ages of 10 to 15 weeks. All experimental procedures were approved by the Dalhousie University Committee for Laboratory Animals and followed the guidelines of the Canadian Council on Animal Care.
Human Tissue Samples and Patient Characteristics
Right atrial tissue samples were obtained from cardiac surgery patients who were in sinus rhythm and had no previous history of arrhythmia. Patient characteristics are listed in Table I in the Data Supplement. All patients gave informed written consent to participate in our study, which was approved by the Research Ethics Board of the Capital Health District Authority.
Peptides
This study used wild-type ANP and mANP, which were both obtained from Bachem (Torrance, CA). mANP (amino acid sequence: SLRRSSCFGGRMDRIGAQSGLGCNSFRYRITARED KQGWA) 11, 27 was synthesized and confirmed by mass spectrometry, amino acid analysis, and high-performance liquid chromatography by Bachem.
Patch Clamping of Atrial Myocytes From Mice and Humans
Right or left atrial myocytes were isolated from mice enzymatically as we have described previously. 13, 28 Human right atrial myocytes were isolated from tissue samples obtained from cardiac surgery patients using similar procedures to those in mice, with some specific modifications as outlined in the Data Supplement. Mouse and human atrial myocytes were used to record APs using the perforated patchclamp technique and I Ca,L and Na + current (I Na ) using the whole-cell patch-clamp technique. The solutions and experimental protocols for these experiments are available in the Data Supplement.
Quantitative Polymerase Chain Reaction
Quantitative gene expression in human right atrial samples was performed using approaches we have described previously. 13, 28 Intron spanning primers were designed for human NPR-A, NPR-B, NPR-C, and GAPDH. Experimental protocols and primer sequences are provided in the Data Supplement.
cAMP Assay cAMP was measured in isolated mouse right atrial myocytes using an HTRF cAMP Femto2 kit (Cisbio) according to manufacturer's instruction (Data Supplement).
High-Resolution Optical Mapping
Patterns of electrical conduction, atrial effective refractory period (ERP), and susceptibility to arrhythmias were studied in isolated atrial preparations using optical mapping techniques we have previously described. 17, 28, 29 Optical mapping was done using the voltage sensitive dye di-4-ANEPPS (10 μmol/L) and blebbistatin (10 μmol/L) to suppress contractile activity. All analyses were performed using custom software. Details are provided in the Data Supplement.
To measure ERP, atrial preparations were given an 8-stimulus drive train at a cycle length of 90 ms followed by a single extra stimulus at progressively shorter cycle lengths. ERP was defined as the shortest coupling interval allowing for capture of the atrial preparation.
For arrhythmia studies, we used S1-S2 pacing protocols in which the atria were paced at a fixed cycle length (90 ms) and then given 3 to 6 premature stimuli at progressively shorter cycle lengths (S2). The details for these experimental approaches are provided in the Data Supplement.
Statistical Analysis
All data are presented as mean±SD. Data were analyzed using a Student t test, 1-way ANOVA with Tukey post hoc test, 1-way repeated measures ANOVA with Tukey post hoc test, or Fisher exact test as indicated in each figure legend. P<0.05 was considered significant.
Results

ANP and mANP Have Opposing Effects on Atrial Myocyte Electrophysiology in Mice
Although circulating concentrations of mANP were found to be higher than those of wild-type ANP in individuals who
WHAT IS KNOWN
• Atrial natriuretic peptide (ANP) is a powerful regulator of atrial function, including atrial electrophysiology.
• A mutation in the ANP gene results in the production of a mutant ANP that has been linked with atrial fibrillation in people; however, the mechanism(s) by which mutant ANP creates a substrate for atrial fibrillation are unknown.
WHAT THE STUDY ADDS
• Wild-type ANP and mutant ANP have opposing effects on atrial electrophysiology, including action potential morphology, L-type Ca 2+ current, and atrial conduction velocity, via distinct receptor-mediated signaling mechanisms.
• Mutant ANP created a substrate for atrial arrhythmias that were associated with disorganized atrial activation patterns, multiple ectopic foci, and reentrant conduction.
• Wild-type ANP was highly protective against atrial arrhythmias suggesting that ANP may be a target to prevent atrial fibrillation.
have this NPPA mutation, 11 our goal was to determine whether ANP and mANP have distinct effects on atrial electrophysiology independent of differences in dose. Therefore, we initially measured the effects of identical doses of wild-type ANP (100 nmol/L) and mANP (100 nmol/L) on AP morphology in mouse right atrial myocytes in basal conditions ( Figure IA in the Data Supplement). These measurements demonstrate that neither ANP nor mANP had any effects on mouse atrial AP properties in basal conditions (Figure IB and Tables II and III in the Data Supplement). Because we have previously shown that I Ca,L is a major target of NPs in the atria, 13, 15 we also measured the effects of ANP and mANP (100 nmol/L doses) on basal I Ca,L in mouse right atrial myocytes ( Figure IC The absence of effects of ANP on AP morphology and I Ca,L in basal conditions is consistent with our previous studies showing that the related peptides BNP and CNP only affect mouse atrial myocyte electrophysiology in the presence of the β-adrenergic receptor agonist isoproterenol. 13 Accordingly, we next measured the effects of ANP and mANP on AP morphology in mouse atrial myocytes after application of isoproterenol (10 nmol/L). In these experiments, ANP and mANP were each applied at doses of 10 and 100 nmol/L to consider the dose dependence of each of these peptides.
The effects of ANP (10 and 100 nmol/L) on mouse atrial AP morphology are illustrated in Figure 1 . Representative recordings ( Figure 1A and 1D) and summary data illustrate that isoproterenol increased (P<0.05) the AP maximum upstroke velocity (V max ; Figure 1B and 1E) and APD at 50% (APD 50 The individuals affected by the NPPA mutation being studied were all heterozygous and thus produce both wild-type ANP and mANP.
11 Accordingly, we next studied the effects of ANP and mANP in combination on mouse atrial myocyte AP morphology. In these studies, we initially applied isoproterenol (10 nmol/L) and then simultaneously applied ANP and mANP (100 nmol/L each). Representative AP recordings ( Figure 3A ) and summary data ( Figure 3B and 3C) demonstrate that, in the presence of isoproterenol, combined application of equimolar doses of ANP and mANP had no effect on V max (P=0.070), APD 50 (P=0.387), APD 70 (P=0.127), or APD 90 (P=0.067) although there was an overall trend toward a reduction in these AP parameters (Table X in the Data Supplement). These findings suggest that when present together at equal doses, the effects of ANP and mANP negate each other.
Next, we measured the effects of ANP and mANP (100 nmol/L each) on I Ca,L in the presence of isoproterenol (10 nmol/L) in mouse right atrial myocytes (Figure 4) . Representative I Ca,L recordings ( Figure 4A ) and time course data ( Figure 4B ) demonstrate that isoproterenol increased atrial I Ca,L and subsequent application of ANP further augmented I Ca,L . These effects were reversible on washout. The stimulatory effects of isoproterenol and ANP are also evident in summary current-voltage relationships ( Figure 4C ). The effects of ANP on atrial I Ca,L were further studied by performing steady-state conductance analysis ( Figure 4D ; Table XI Consistent with the AP data presented above, representative I Ca,L recordings ( Figure 4E ), time course data ( Figure 4F ), and summary current-voltage relationships ( Figure 4G ) demonstrate that mANP (100 nmol/L) had the opposite effects to ANP and decreased atrial I Ca,L in the presence of isoproterenol. Conductance analysis demonstrates that mANP decreased I Ca,L and G max (P<0.05) and shifted the V 1/2(act) (P<0.05) to more positive membrane potentials ( Figure 4H ; Table XII in the Data Supplement ). Thus, as was the case for AP measurements, ANP and mANP have distinct and opposing effects on atrial I Ca,L .
To assess the dose dependence of the effects of ANP and mANP on atrial I Ca,L , we measured the effects of each peptide at concentrations between 1 and 100 nmol/L (in the presence of isoproterenol) on peak right atrial I Ca,L ( Figure II in the Data Supplement). These studies demonstrate that ANP and mANP modulated I Ca,L at each dose tested. There was no significant difference in the magnitude of the effects of ANP (P=0.30) and mANP (P=0.10) at doses of 10 and 100 nmol/L although there was a trend toward larger effects at the higher dose. In contrast, the effects of ANP and mANP at 1 nmol/L doses were smaller (P<0.05) than those of ANP and mANP at the higher 2 doses. We also measured the effects of ANP and mANP (100 nmol/L each) on I Ca,L in mouse left atrial myocytes ( Figure III in the Data Supplement). These data illustrate that the effects of ANP and mANP on I Ca,L are similar in right and left atrial myocytes.
Because ANP and mANP had opposing effects on AP V max , which is importantly influenced by I Na , we also measured the effects of isoproterenol (10 nmol/L) and each peptide (100 nmol/L) on mouse atrial I Na (Figure IV and Table XIII and XIV in the Data Supplement). I Na current-voltage relationships and steady-state conductance analysis demonstrate that neither isoproterenol, ANP, or mANP had any effects on atrial I Na , suggesting that I Ca,L is the key ion channel regulated by these peptides (Discussion).
Role of NPR-A and NPR-C in Mediating the Effects of ANP and mANP on I Ca,L
We have previously demonstrated that NPs (BNP and CNP) can modulate I Ca,L via the guanylyl cyclase-linked NPR-A/B receptors and NPR-C. 13, 22 Furthermore, ANP and mANP have each been shown to bind NPR-A and NPR-C. 27 To determine the mechanism for the opposing effects of ANP and mANP on atrial I Ca,L , we measured the effects of these 2 peptides (100 nmol/L doses) on I Ca,L (in the presence of isoproterenol; 10 nmol/L) in right atrial myocytes from NPR-C −/− mice (Figure 5 ). These data demonstrate that ANP ( Figure 5A -5C) increased isoproterenol-stimulated I Ca,L and that the magnitude of the effect of ANP was similar to that observed in wild-type mice (compare with Figure 4) . Strikingly, the inhibitory effects of mANP on I Ca,L (in the presence of isoproterenol) were completely absent in atrial myocytes from NPR-C −/− mice. The data in Figure 5D -5F demonstrate that isoproterenol increased I Ca,L as expected but mANP had no effects on I Ca,L density. Thus, the ability of ANP to increase I Ca,L is maintained in NPR-C −/− atrial myocytes, whereas the inhibitory effect of mANP on I Ca,L is absent in mice lacking NPR-C receptors. This suggests that ANP and mANP signal via separate pathways.
Because the stimulatory effect of ANP on atrial I Ca,L was maintained in NPR-C −/− atrial myocytes, we hypothesized that this effect must be mediated by NPR-A, the only other receptor that ANP binds to physiologically. 10 This hypothesis was tested using the NPR-A antagonist A71915. 30 We have previously demonstrated that A71915 has no direct effects on atrial I Ca,L
13
; therefore, we applied A71915 (500 nmol/L) concomitantly with isoproterenol (10 nmol/L) for 5 minutes followed by application of ANP (100 nmol/L) in mouse right atrial myocytes. These data (Figure V in the Data Supplement) demonstrate that A71915 completely blocked the ability of ANP to increase atrial I Ca,L .
ANP and mANP Have Opposing Effects on cAMP Production in Mouse Atrial Myocytes
The data described above demonstrate that ANP increases I Ca,L via NPR-A, whereas mANP decreases I Ca,L via NPR-C. We have previously demonstrated that NPR-A-mediated increases in I Ca,L involve the inhibition of phosphodiesterase-3 (PDE3) by cyclic GMP, 13 which would increase cAMP by preventing its hydrolysis. Conversely, NPR-C activation is known to reduce cAMP levels via the activation of inhibitory G-proteins. 23 ,31 Accordingly, we hypothesized that the effects of ANP would be associated with increased cAMP levels, whereas the effects of mANP would be associated with decreased cAMP production. This was tested using a cAMP assay in isolated mouse right atrial myocytes. In these experiments (Figure VI in the Data Supplement), the effects of ANP (100 nmol/L) and mANP (100 nmol/L) on intracellular cAMP levels were measured in basal conditions and in the presence of isoproterenol (10 nmol/L).
Consistent with an absence of effects on mouse atrial myocyte electrophysiology (AP morphology, I Ca,L ) in basal conditions, neither ANP (P=0.463) nor mANP (P=0.445) had any effect on cAMP concentrations in the absence of isoproterenol. In contrast, in the presence of isoproterenol, ANP and mANP had opposing effects on intracellular cAMP concentrations. Specifically, isoproterenol increased (P<0.05) cAMP as expected. Application of ANP in the presence of isoproterenol resulted in a further increase in cAMP (P<0.05), whereas application of mANP in the presence of isoproterenol resulted in lower cAMP concentrations (P<0.05). Thus, the opposing effects of ANP and mANP on atrial myocyte electrophysiology (in the presence of isoproterenol) occur in association with opposing effects of these 2 peptides on intracellular cAMP concentrations.
Effects of ANP and mANP on Human Right Atrial Myocyte I Ca,L
The next set of experiments sought to translate our findings in mouse atrial myocytes to the human heart. Using quantitative polymerase chain reaction, we assessed the mRNA expression We also isolated atrial myocytes from human right atrial appendage samples and measured the effects of identical doses of ANP (100 nmol/L) and mANP (100 nmol/L) on human right atrial I Ca,L in baseline conditions and in the presence of isoproterenol (10 nmol/L). Human I Ca,L was recorded Representative I Ca,L recordings ( Figure 6A ) and summary data ( Figure 6B ) illustrate that ANP reversibly increased basal I Ca,L in human atrial myocytes. The magnitude of this effect was comparable with that seen in mice. Notably, however, this stimulatory effect of ANP on human atrial I Ca,L was observed without the requirement for prestimulation with isoproterenol. Next, we measured the effects of mANP on basal I Ca,L in human right atrial myocytes. Representative recordings ( Figure 6C ) and summary data ( Figure 6D ) demonstrate that, as in the mouse, mANP had no effect on I Ca,L density in human atrial myocytes in the absence of isoproterenol. Finally, we measured the effects of ANP and mANP on human right atrial I Ca,L in the presence of isoproterenol (10 nmol/L; Figure 6E -6H). Consistent with our findings in mouse myocytes, ANP increased (P<0.05) isoproterenol-stimulated I Ca,L , whereas mANP inhibited (P<0.05) isoproterenol-stimulated I Ca,L in human atrial myocytes. These effects of ANP and mANP were fully reversible after washout.
Our findings in human right atrial myocytes demonstrate that, similar to the mouse, the main effect of ANP is to increase I Ca,L , whereas mANP decreases I Ca,L ; however, a notable difference was that ANP was able to stimulate I Ca,L in basal conditions and in the presence of isoproterenol in human atrial myocytes, whereas in mice, ANP only increased I Ca,L in the presence of isoproterenol. We have previously shown that BNP and CNP (NPs closely related to ANP) also increase mouse atrial I Ca,L in the presence of isoproterenol but not in basal conditions and that this is because mouse atria do not have constitutive PDE3 activity, which is necessary for the stimulatory effects of these NPs on atrial I Ca,L.
13,32
On the basis of this, we hypothesized that human atrial myocytes must have constitutive PDE3 activity, which would explain the ability of ANP to increase human atrial I Ca,L in basal conditions. To test this hypothesis, we measured the effects of the PDE3 inhibitor milrinone (10 µmol/L) on basal I Ca,L in human right atrial myocytes ( Figure IX in the Data Supplement). These data illustrate that milrinone potently, and reversibly, increased human atrial I Ca,L confirming that, unlike the mouse, 32 human atrial myocytes display constitutive PDE3 activity.
ANP and mANP Have Opposing Effects on Electrical Conduction in the Mouse Atria
Alterations in electrical conduction within the atria can contribute importantly to susceptibility to AF 4, 33 ; therefore, we used high-resolution optical mapping to determine the effects of ANP and mANP on activation patterns in the mouse atria. These studies were performed in an isolated atrial preparation 17, 34, 35 ( Figure X in the Data Supplement) and used an intermediate dose of ANP (50 nmol/L) and mANP (50 nmol/L). Representative activation maps are presented in control conditions, after application of isoproterenol (10 nmol/L) and following subsequent application of ANP or mANP in the presence of isoproterenol ( Figure 7A) . These activation maps demonstrate that the first electric breakthrough occurs in the right atrial posterior wall, which corresponds to the location of the sinoatrial node, 17 and that conduction propagates from this site into the right and left atrial appendages. As expected, isoproterenol sped conduction time throughout the atrial preparation (fewer isochrones with more space between successive isochrones in the presence of isoproterenol). Application of ANP in the presence of isoproterenol further sped conduction, whereas mANP had the opposite effect and slowed electrical conduction time across the atrial preparation.
To further quantify the effects of ANP and mANP (in the presence of isoproterenol) on electrical conduction, we measured local conduction velocity (CV) in the right and left atrial appendages using a previously described approach 17 (Methods). Initially, CV was measured in atrial preparations in sinus rhythm where the cycle length was free to change. Summary data demonstrate that, as expected, isoproterenol decreased (P<0.05) cycle length, which corresponds to an increase in heart rate. ANP further shortened (P<0.05) the isoproterenol-stimulated cycle length ( Figure 7B ). In contrast, mANP tended to increase cycle length, although this did not reach statistical significance (P=0.09; Figure 7B ).
Analysis of atrial CV (in sinus rhythm) demonstrates that isoproterenol increased (P<0.05) CV in the right and left atria and that subsequent application of ANP in the presence of isoproterenol further increased (P<0.05) right atrial and left atrial CVs ( Figure 7C ). These changes in CV are consistent with the effects of isoproterenol and ANP on atrial AP V max (Figure 1 ), which is a key determinant of CV in the heart. 36 Once again, mANP had the opposite effects to ANP and decreased (P<0.05) CV in the right and left atria ( Figure 7D ). This is in agreement with the finding that mANP also decreased V max (Figure 2 ) in isolated atrial myocytes. To account for the possibility of rate-dependent effects, we also measured right and left atrial CV in atrial preparations paced at a fixed cycle length of 90 ms ( Figure 7E and 7F ). These data demonstrate similar effects of ANP and mANP on atrial CV to those observed in sinus rhythm.
Our optical mapping studies also enabled us to assess changes in APD in the intact atrial preparation by measuring optical APs (Figure XI in the Data Supplement). Optical APs were measured in the right atrial myocardium after application of isoproterenol (10 nmol/L) and then ANP or mANP (50 nmol/L each). Isoproterenol increased (P<0.05) APD 70 in atrial preparations, and consistent with our studies in isolated myocytes, subsequent application of ANP further increased APD 70 (P<0.05), whereas mANP decreased isoproterenolstimulated APD 70 .
Because changes in APD are known to affect atrial ERP, we used programmed stimulation to measure the effects of isoproterenol, ANP, and mANP on ERP in isolated atrial preparations ( Figure 
Effects of ANP and mANP on Arrhythmogenesis
Finally, we used high-resolution optical mapping in conjunction with atrial pacing/programmed stimulation to study the effects of ANP and mANP on inducibility of arrhythmias in mouse atrial preparations. These pacing studies were performed in atrial preparations in the presence of isoproterenol (10 nmol/L) and either ANP (50 nmol/L) or mANP (50 nmol/L) to mimic the conditions in which the 2 peptides elicited opposing effects on atrial conduction and ERP. Figure 8A and 8B illustrate activation maps before and after atrial pacing in the presence of isoproterenol and ANP. These images demonstrate that the heart was in sinus rhythm and activation patterns were normal (ie, conduction initiated in the right atrial posterior wall and then propagated uniformly throughout the atrial preparation) before and after pacing. Figure 8C illustrates a representative activation map in the presence of isoproterenol and mANP before pacing. This map demonstrates a normal conduction pattern although, consistent with the data in Figure 7 , conduction was slowed in the presence of mANP compared with ANP. Strikingly, atrial pacing in the presence of mANP resulted in the induction of atrial arrhythmias ( Figure 8D ). Specifically, delivery of premature stimuli resulted in the occurrence of multiple points of simultaneous activation (red color) including ectopic foci in the right atrium near the pectinate muscles. These ectopic foci were associated with a re-entrant pattern of conduction (white arrow in Figure 8D ) in the right atrium. In this example, we also observed conduction to the left atrium via an activation point in the right atrial posterior wall that was similar to the normal initial activation point before pacing (black arrow in Figure 8D) ; however, conduction to the right atrial appendage from the normal excitation point was blocked. In other instances, we observed similar re-entrant patterns of conduction in the right atrium with no propagation to the left atrium (not shown). Summary data ( Figure 8E ) demonstrate that in the presence of isoproterenol and ANP, all atrial preparations remained in normal sinus rhythm and no arrhythmias were induced after atrial pacing in these conditions. In contrast, we observed arrhythmias in 62.5% of hearts (5/8 hearts; P<0.05) after atrial pacing in the presence of isoproterenol and mANP. In all cases, these arrhythmias were characterized by disorganized activation patterns, re-entrant conduction patterns, and multiple ectopic foci similar to those shown in Figure 8 . Thus, mANP-treated hearts were highly susceptible to induced arrhythmias, whereas hearts treated with ANP were protected.
Discussion
In this study, we have used mouse and human tissues to compare the effects of wild-type ANP and mANP (which has been associated with AF in the human population). Previous work that measured monophasic APs in rat hearts demonstrated that mANP could decrease APD. 11 Furthermore, the human patients affected by this mutation had circulating levels of mANP that were 5 to 10× greater than those of wild-type ANP. 11 Subsequent biochemical studies showed that mANP was much more resistant to proteolytic degradation, which likely explains the elevated circulating levels of this mutant peptide compared with normal ANP. 27 These findings led to the hypothesis that mANP functions similarly to ANP but with enhanced effects because of the profound elevation in plasma concentrations of the peptide and that this could predispose these patients to AF. Although the high circulating levels of mANP may contribute to its proarrhythmic actions, the specific electrophysiological effects of mANP and the mechanism(s) through which it elicits its effects have not been previously studied.
We studied the effects of ANP and mANP using identical doses (1-100 nmol/L) to determine whether mANP has unique effects on atrial electrophysiology independently of differences in plasma concentration. Surprisingly, we found that ANP and mANP had distinct and opposing effects on atrial electrophysiology (including V max , APD, I Ca,L , CV, and ERP). The stimulatory effects of ANP and the inhibitory effects of mANP on I Ca,L were found to be similar in right and left atrial myocytes from mice. When ANP and mANP were applied concomitantly at identical doses, we observed no effect on atrial electrophysiology, indicating that the peptides negated each other's effects. Our mechanistic experiments using NPR-C −/− mice and an NPR-A antagonist conclusively demonstrate that ANP affects atrial electrophysiology via the NPR-A receptor, whereas mANP signals via NPR-C.
These novel findings strongly suggest that mANP may be proarrhythmic not only because it circulates at a higher concentration than ANP but also because it elicits electrophysiological effects that are distinct from those of ANP (ie, mANP is not simply enhancing the effects of ANP in a concentrationdependent manner). Because the circulating concentration of mANP was so much higher than that of ANP in individuals affected by this mutation, it is possible that the effects of mANP may be more robust than those of ANP and that the effects of mANP may dominate in vivo. We also found that the expression of NPR-C, which mediates the effects of mANP, is much higher in human atria than that of NPR-A, which may further enhance the effects of mANP compared with ANP.
Many of the effects of NPs on the heart are dose dependent. 13, 14, 17 Our electrophysiological studies demonstrate that the effects of ANP and mANP on atrial electrophysiology are comparable at doses from 10 to 100 nmol/L and smaller, but still significant, at doses as low as 1 nmol/L. Although some of these doses of ANP are higher than typical circulating levels, 10 it is possible that mANP, because of its enhanced resistance to proteolytic degradation, 27 could achieve low nanomolar concentrations in the circulation, particularly in conditions where atrial stretch is enhanced and NP production is increased. Furthermore, it is important to note that because ANP (and mANP) are produced in atrial myocytes, the local concentrations of these peptides in the atria are likely to be much higher than circulating concentrations. All of these factors suggest that the effects of ANP and mANP we have described at low nanomolar concentrations are physiologically relevant.
Interestingly, although we observed clear effects of isoproterenol, ANP, and mANP on V max and atrial CV, we found no direct effects of any of these compounds on atrial I Na . This was surprising because I Na is the main determinant of V max , which in turn contributes importantly to CV. 36 Furthermore, we showed that the electrophysiological effects of ANP and mANP are associated with changes in cAMP production. Several studies have shown that cAMP and protein kinase A can directly modulate voltage-gated sodium channels, [37] [38] [39] although not all studies agree on this. 40, 41 The lack of direct effects of ANP and mANP on atrial I Na in our study suggests that ANP and mANP are modulating V max and atrial CV via their robust effects on I Ca,L . Consistent with this hypothesis, changes in calcium are known to have potent effects on V max 42 and calcium is known to regulate sodium channels. [43] [44] [45] Thus, ANP and mANP could modulate I Na secondary to changes in I Ca,L . In our I Na recordings, I Ca,L is blocked and Ca 2+ transients are suppressed, which could explain why we did not observe any effects of ANP/ mANP on I Na in our experimental conditions.
It is also possible that changes in I Ca,L could directly contribute to changes in V max and CV as I Ca,L is known to have effects on electrical conduction in some conditions. 36 Although these effects are smaller than those exerted by I Na , they may be important in the atrial myocardium because of the expression of Ca V 1.3 L-type Ca 2+ channels in this region of the heart. 46,47 Ca V 1.3-mediated I Ca,L activates at more negative membrane potentials than Ca V 1.2, 46 which could result in a greater contribution by I Ca,L to the AP upstroke in the atrial myocardium. Our I Ca,L recordings were done using a voltage clamp protocol that measures total I Ca,L (Ca V 1.2 and Ca V 1.3 dependent). The left shifts in I Ca,L V 1/2(act) elicited by isoproterenol and ANP could result in a greater influence of I Ca,L on V max in atrial myocytes and contribute to the increases in V max we observed. In contrast, the right shift in I Ca,L V 1/2(act) elicited by mANP could reduce V max . Ca V 1.2 and Ca V 1.3 are both known to be regulated by cAMP and protein kinase A [48] [49] [50] ; therefore, we anticipate that both channels are being similarly modulated by isoproterenol, ANP, and mANP; however, we have not studied each channel separately in this study.
Electrical re-entry is thought to be a major factor in AF with the wavelength of re-entry being determined by the product of the atrial ERP and atrial CV. 4, 33, 51, 52 Reductions in wavelength that favor the occurrence of AF are commonly associated with changes in ion-channel function or regulation in atrial myocytes. [53] [54] [55] Our novel studies demonstrate that mANP decreases APD (which corresponds to a reduction in atrial refractory period) and V max (which is consistent with the slowing of atrial CV). In agreement with these findings, direct assessment of refractoriness in intact atrial preparations illustrates that mANP shortened atrial ERP. These effects on CV and ERP would be expected to decrease the wavelength of re-entry and could explain how mANP leads to the occurrence of AF. In contrast, and consistent with our previous studies of the effects of BNP and CNP on atrial electrophysiology, 13, 14, 17 our experiments show that wild-type ANP increases APD and V max , speeds electric conduction in both the right and left atria, and increases atrial ERP. These effects would increase the wavelength of re-entry and would be expected to decrease the likelihood of AF, suggesting that wild-type ANP could be antiarrhythmic. Consistent with these concepts, we found that mANP greatly increased the susceptibility to arrhythmias during pacing studies in atrial preparations. These arrhythmias were characterized by re-entrant conduction patterns, ectopic foci of activation, and conduction block, all of which are associated with atrial flutter and AF. [56] [57] [58] In agreement with a key role for I Ca,L in the occurrence of atrial arrhythmias in the presence of mANP, reductions in both Ca V 1.2 and Ca V 1.3 expression or function are known to profoundly increase susceptibility to AF in animal models and humans. 47, [58] [59] [60] [61] This study indicates that changes in cAMP are central to the electrophysiological effects of wild-type NPs, as well as mANP, in the heart. Effects mediated by the NPR-A receptor involve a cyclic GMP-mediated inhibition of PDE3, which would lead to elevated cAMP levels, whereas effects mediated by NPR-C involve the inhibition of adenylyl cyclase and reductions in cAMP. Importantly, this study shows that the electrophysiological effects of ANP and mANP were only evident in the mouse in the presence of isoproterenol. This is in agreement with the observations that neither ANP nor mANP had any effects on cAMP production in the absence of isoproterenol in mouse atrial myocytes and further supports the conclusion that the electrophysiological effects of ANP and mANP are associated with changes in cAMP signaling. Changes in cAMP concentration are known to affect I Ca,L via changes in phosphorylation of L-type Ca 2+ channels by protein kinase A, which shifts the voltage dependence of activation and increases the channel open probability. 62 Our biophysical analyses showing that the effects of both ANP and mANP on atrial I Ca,L are associated with shifts in the V 1/2 of channel activation strongly suggest that these peptides causes cAMP-dependent changes in protein kinase A phosphorylation of L-type Ca 2+ channels. Our study demonstrates that the distinct effects of ANP and mANP on I Ca,L are also present in human atrial myocytes with some minor differences compared with the mouse. Specifically, in mice, ANP only increased atrial I Ca,L in the presence of isoproterenol, whereas in humans, ANP potently increased atrial I Ca,L in basal conditions and in the presence of isoproterenol. This is because the stimulatory effect of NPs on atrial I Ca,L (mediated by NPR-A) occurs via the inhibition of PDE3. 13 We have previously shown that mouse atrial myocytes lack constitutive PDE3 activity, 32 which is why NPs, including ANP, have no effect on basal atrial electrophysiology in mice. 13 In contrast, this study shows that human atrial myocytes have robust constitutive PDE3 activity, and this explains why ANP can modulate human I Ca,L in basal conditions. Our observation that human atrial myocytes have constitutive PDE3 activity is consistent with previous studies showing similar results. 63, 64 The inhibitory effects of mANP on atrial I Ca,L were similar in mice and humans and were only observed in the presence of isoproterenol. This is highly consistent with our previous studies demonstrating that NPR-C-mediated effects of NPs on cardiac electrophysiology are most prominent in the setting of β-adrenergic receptor activation. 13, 14, 16, 17 All of our human I Ca,L measurements were performed in right atrial myocytes. On the basis of our data showing that the effects of ANP and mANP are similar in right and left atrial myocytes in mice, we hypothesize that this is the case in the human heart as well; however, we have not directly measured the effects of NPs in human left atrial myocytes.
The similarities between the electrophysiological effects of ANP and mANP in mice and humans (particularly in the presence of isoproterenol) strongly suggest a mechanism for how mANP causes AF in humans. Nevertheless, extrapolation of our mouse arrhythmogenesis studies to humans must be done with some caution as our results do demonstrate some differences in PDE3 activity and how I Ca,L is regulated by NPs in mice and humans. Clearly, additional studies in humans are warranted.
Although our study provides novel insight into how mANP could create a substrate for AF, our experiments also demonstrate that wild-type ANP is protective against atrial arrhythmias, possibly in association with its AP lengthening and CV speeding effects. These effects of ANP would be expected to increase the wavelength of re-entry and decrease the likelihood of AF being initiated. The antiarrhythmic effects of wild-type ANP have not been well studied; however, there is evidence that ANP can reduce the incidence of postoperative AF during cardiothoracic surgeries. [65] [66] [67] To better appreciate the role of wild-type ANP in human AF, it will be important to study the electrophysiological effects of ANP in atrial myocytes from human patients with a history of AF. AF is associated with electrical remodeling, including alterations in Ca 2+ -channel expression, 59 which may affect the effects of ANP on I Ca,L in this setting. For example, it has recently been shown that the effects of nitric oxide on atrial I Ca,L are attenuated and distinct, whereas the responsiveness to isoproterenol is preserved, in atrial myocytes isolated from patients with chronic AF. 64 It is presently unknown how chronic AF affects the electrophysiological effects of ANP.
In conclusion, we have studied the effects of ANP and mANP on atrial electrophysiology in mice and humans. Our study provides new insight into the unique electrophysiological effects of mANP and suggests that this mutation promotes AF by decreasing AP V max , shortening atrial APD, decreasing I Ca,L , and slowing atrial CV. In contrast, wild-type ANP has the opposite effects, which would be expected to decrease the susceptibility to AF by increasing the wavelength of re-entry, although additional studies are required to fully assess the effect of differences between mouse and human atrial electrophysiology. These findings advance our understanding of the electrophysiological effects of wild-type and mutated NPs in the heart and suggest that the NP system could be a target for treating or preventing AF.
